European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- ((link)) Jun 2026

[Granulation / Blending] ──> [In-Process Mechanical Testing] ──> [Microbiological & Divisibility Quality Checks]

For manufacturers, compliance is mandatory for market access. This influences decisions on formulation, process design, and selection of analytical methods. For instance, a manufacturer must demonstrate that their product passes the relevant tests (e.g., friability, disintegration) before it can be released. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

In the complex world of pharmaceutical manufacturing, consistency isn't just a goal—it's a legal requirement. For anyone operating within the 39 member states of the European Pharmacopoeia Convention European Pharmacopoeia (Ph. Eur.) Monograph 0478 By adopting the standards and guidelines set out

This blog post provides an overview of the , which serves as the legally binding standard for tablets marketed in signatory states. disintegration) before it can be released.

By adopting the standards and guidelines set out in the "Tablets -0478-" monograph, the pharmaceutical industry can ensure that tablets are produced and controlled to a high standard, ultimately benefiting patients and public health.

Monograph 0478 states that impurities come from two sources:

The "Tablets -0478-" monograph is essential for manufacturers, regulators, and control laboratories involved in the development, production, and quality control of tablets. The monograph provides a comprehensive framework for evaluating the quality of tablets and ensures that medicinal products available to patients in Europe meet the required standards.